{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Smith-Byrne K"],"funding":["Cancer Research UK","World Health Organization","National Institute for Health Research (NIHR)","NCI NIH HHS","National Institutes of Health","Wellcome Trust"],"pagination":["1966-1974"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9530646"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(10)"],"pubmed_abstract":["<h4>Background</h4>Tobacco exposure causes 8 of 10 lung cancers, and identifying additional risk factors is challenging due to confounding introduced by smoking in traditional observational studies.<h4>Materials and methods</h4>We used Mendelian randomization (MR) to screen 207 metabolites for their role in lung cancer predisposition using independent genome-wide association studies (GWAS) of blood metabolite levels (n = 7,824) and lung cancer risk (n = 29,266 cases/56,450 controls). A nested case-control study (656 cases and 1,296 matched controls) was subsequently performed using prediagnostic blood samples to validate MR association with lung cancer incidence data from population-based cohorts (EPIC and NSHDS).<h4>Results</h4>An MR-based scan of 207 circulating metabolites for lung canc"],"journal":["Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"],"pubmed_title":["Circulating Isovalerylcarnitine and Lung Cancer Risk: Evidence from Mendelian Randomization and Prediagnostic Blood Measurements."],"pmcid":["PMC9530646"],"funding_grant_id":["001","29017","U19CA203654","C18281/A29019","29019","U19 CA203654"],"pubmed_authors":["Agudo A","Sandanger TM","Kaaks R","Guida F","Nost TH","Amos CI","Richards JB","Schulze MB","Weiderpass E","Imaz L","Hung RJ","Grankvist K","Kuhn T","Cerani A","Gram IT","McKay JD","Schibli D","Brennan P","Zhou S","Barranco MR","Vineis P","Chirlaque-Lopez MD","Pala V","Aleksandrova K","Barricarte A","Smith-Byrne K","Johansson M","Martin RM","Han J","Travis RC","Bochers CH","Robbins HA"],"additional_accession":[]},"is_claimable":false,"name":"Circulating Isovalerylcarnitine and Lung Cancer Risk: Evidence from Mendelian Randomization and Prediagnostic Blood Measurements.","description":"<h4>Background</h4>Tobacco exposure causes 8 of 10 lung cancers, and identifying additional risk factors is challenging due to confounding introduced by smoking in traditional observational studies.<h4>Materials and methods</h4>We used Mendelian randomization (MR) to screen 207 metabolites for their role in lung cancer predisposition using independent genome-wide association studies (GWAS) of blood metabolite levels (n = 7,824) and lung cancer risk (n = 29,266 cases/56,450 controls). A nested case-control study (656 cases and 1,296 matched controls) was subsequently performed using prediagnostic blood samples to validate MR association with lung cancer incidence data from population-based cohorts (EPIC and NSHDS).<h4>Results</h4>An MR-based scan of 207 circulating metabolites for lung canc","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-05-10T03:19:58.92Z","creation":"2025-04-06T03:41:54.545Z"},"accession":"S-EPMC9530646","cross_references":{"pubmed":["35839461"],"doi":["10.1158/1055-9965.EPI-21-1033"]}}